Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes | Zendy

Kausik K. Ray | Zendy; Stephen J. Nicholls | Zendy; Kevin A. Buhr | Zendy; Henry N. Ginsberg | Zendy; Jan O. Johansson | Zendy; Kamyar KalantarZadeh | Zendy; Ewelina Kulikowski | Zendy; Peter P. Tóth | Zendy; Norman C.W. Wong | Zendy; Michael Sweeney | Zendy; Gregory G. Schwartz | Zendy

Open Access

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes

Author(s) -

Kausik K. Ray,

Stephen J. Nicholls,

Kevin A. Buhr,

Henry N. Ginsberg,

Jan O. Johansson,

Kamyar KalantarZadeh,

Ewelina Kulikowski,

Peter P. Tóth,

Norman C.W. Wong,

Michael Sweeney,

Gregory G. Schwartz

Publication year - 2020

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2020.3308

Subject(s) - medicine , acute coronary syndrome , type 2 diabetes , adverse effect , diabetes mellitus , cardiology , intensive care medicine , myocardial infarction , endocrinology

Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis. Pooled phase 2 data suggest favorable effects on clinical outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research